Abstract 11691: Three Months of Dual Antiplatelet Therapy is Optimal Time for Mortality and Morbidity Benefit Post Coronary Artery Bypass Grafting - Results of an In-depth, Retrospective Review of a Large Series of Patients From a Single Center

IntroductionBenefits of dual anti platelet therapy (DAPT) in patients undergoing coronary artery bypass graft (CABG) surgery has previously been reported by us and others . Little has been reported on whether DAPT benefits are more pronounced in the early months than later on .HypothesisSince anti-platelet therapy targets primarily acute phase of thrombosis, it may be hypothesized that the benefits of DAPT are more likely to be drawn in the first few months after surgery.MethodsWe compared incidence proportions of all-cause mortality, cardiovascular (CV) mortality and major adverse cardiovascular events (MACE) between patients receiving aspirin mono-therapy( AMT) vs DAPT after surgery. Cut off time period for early vs late events was 3 months after surgery. MACE was defined as composite of acute coronary syndrome (ACS), cerebrovascular accident (CVA) and CV mortality. Multivariate regression analysis was performed. Odds ratios and 95% confidence intervals were calculated to investigate the predictive relevance of risk factors. Significance was based on a two-tailed p-value less than 0.05. All statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, NY).ResultsBetween 2012 and 2015, 2476 patients were identified for analysis after excluding those who had concomitant valve surgery, required chronic anticoagulation, or were lost to follow-up. Early post-operative event analysis showed patients prescribed DAPT (n=1459) presented lower all-cause mortality (Odds Ratio {OR} 0.108, 95 Confidence Interval {CI} 0.053-0.220; p=